Becton, Dickinson(BDX) Prnewswire·2024-07-10 16:12Core Insights - BD (Becton, Dickinson and Company) is addressing a supply issue related to its BACTEC™ blood culture vials, which is not expected to have a material financial impact on the company [1][2][4] - The company is taking measures to mitigate the impact on patient care by manually allocating blood culture vials and advising customers to prioritize usage based on clinical needs [2][4] Company Overview - BD is a leading global medical technology company with a commitment to improving medical discovery, diagnostics, and care delivery [1][3] - The company employs approximately 70,000 individuals and operates in nearly every country, collaborating with organizations to tackle global health challenges [1] Supply Chain Management - The company is experiencing reduced availability of blood culture vials from its supplier and is implementing various strategies to address this issue, including providing manufacturing expertise to the supplier and modifying production schedules [4] - BD is also collaborating with the U.S. Food and Drug Administration to explore options for mitigating supply delays [4] Communication with Stakeholders - BD has communicated with healthcare providers regarding the supply situation and is actively working to ensure that the majority of global demand is met [2][4] - The company has set up a dedicated website for updates on the BACTEC™ blood culture vials supply [5]